

Bavarian Nordic is One of the Largest Pure-Play Vaccine Companies Globally

Bavarian Nordic is a fully integrated vaccine company focused on the research and development, manufacturing, and commercialization of life-saving vaccines.


We are a global leader in smallpox and mpox vaccines, which have been developed through our long-standing

partnership with the U.S. government to enhance public health preparedness, and have a strong portfolio of vaccines for travelers and endemic diseases. Our manufacturing sites and network of manufacturing partners provide both reliability and flexibility as a vaccine supplier.

Our Global Presence in 2023

Founded in 1994 as a collaboration between Danish investors and German scientists, we have expanded our presence and operations globally.

- Covered by Bavarian Nordic
- Covered by distribution partners



We are a pioneering force in vaccines – expanding our reach and impact through life-changing solutions. Protecting lives every day is an essential part of our DNA in Bavarian Nordic, and we aspire to develop vaccines that address unmet medical needs for the greater good of the global society.

Committed to Helping Save and Improve Lives



Pioneering Research & Development

Strong heritage in vaccine development and cutting-edge technology drives our innovation to fight existing and emerging diseases



Expertise in Vaccine Manufacturing

Expertise in vaccine manufacturing and fill-and-finish capabilities enables our end-to-end commercial-scale manufacturing



Commercial Excellence

Established commercial infrastructure with presence in key US and EU markets drives profitable growth of our expanding vaccine portfolio

At a Glance

Founded: **1994** CEO: **Paul Chaplin**

Global Headquarters: **Hellerup, Denmark** Number of Employees: **1,400+ / 150 in the US** (as of March 2024)

US Headquarters: **Durham, NC**

Revenue (FY 2023): **\$7,062 mDKK / \$1.05B USD** (124% growth over 2022)


Market Capitalization: **~\$12B DKK / ~\$2B USD** (as of March 18, 2024)

Market Trading: Nasdaq Copenhagen (OMX): **BAVA** Level 1 ADR program in the US: **BVNR**

2023 Highlights


- 10 million + vaccine doses** were delivered to more than 40 countries in 2023
- Acquired travel health portfolio** from Emergent BioSolutions that included two commercial products and a late-stage infectious disease vaccine candidate
- Successful Phase 3 results** reported for chikungunya vaccine candidate with potential commercial launch in 2025
- Grew organization by 41%** through acquisition and organic growth

A Strong Heritage in Vaccine Development



We have established a diverse portfolio of in-house developed and acquired products addressing infectious diseases across the globe. Our commercial vaccines are available in more than 30 countries, and through our partnerships with governments and international organizations, we are working to increase the availability of important vaccines to improve public preparedness in even more countries.


Our Evolving US Vaccines Portfolio Addresses Global Health Risks & Unmet Needs



JYNNEOS®
(Smallpox and Monkeypox Vaccine, Live, Non-replicating)

JYNNEOS®
(Smallpox & Monkeypox Vaccine, Live, Non-Replicating)


JYNNEOS is approved for the prevention of smallpox and mpox disease in adults 18 years of age and older determined to be at high risk for smallpox or mpox infection.



RabAvert®
Rabies Vaccine

RabAvert®
(Rabies Vaccine)


RabAvert is indicated for pre-exposure vaccination, in both primary series and booster dose, and for post-exposure prophylaxis against rabies in all age groups.



Vivotif®
(Typhoid Vaccine Live Oral Ty21a) Capsules

VIVOTIF®
(Typhoid Vaccine Live Oral Ty21a)

VIVOTIF is indicated for immunization of adults and children greater than 6 years of age against disease caused by *Salmonella typhi*.



Vaxchora®
(Cholera Vaccine, Live, Oral) 100 mL Oral Suspension

VAXCHORA®
(Cholera Vaccine, Live, Oral)

VAXCHORA is a vaccine indicated for active immunization against disease caused by *Vibrio cholerae serogroup O1* in persons 2 through 64 years of age traveling to cholera-affected areas.

Please see full Prescribing Information for [JYNNEOS](#), [RabAvert](#), [VIVOTIF](#), and [VAXCHORA](#).

Our Global Product Portfolio

We are a leading supplier of travel vaccines and a preferred partner with governments on vaccines for public preparedness.

Public Preparedness:

JYNNEOS®
(Smallpox and Monkeypox Vaccine, Live, Non-replicating)

Marketed as Imvamune® and/or Imvanex® outside the US

Our Pipeline:

CHIKV VLP
Chikungunya virus BLA & MAA submission planned in 2024

MVA-BN WEV
Equine Encephalitis Phase 2 planned in 2024

Travel Health:

RabAvert®
Rabies Vaccine
(Marketed as Rabipur® outside the US)

Encepur®
(Tick-borne encephalitis vaccine (inactivated, adsorbed))
(Not available in the US)

Vaxchora®
(Cholera Vaccine, Live, Oral) 100 mL Oral Suspension

Vivotif®
(Typhoid Vaccine Live Oral Ty21a) Capsules

Third-party travel health products marketed and distributed by Bavarian Nordic in select markets:

Hepelisav-B®
Hepatitis B
(Not available in the US)

Dukoral®
Cholera

Ixiaro®
Japanese encephalitis